Study |
Time |
Treatment |
Outcome (scale) |
N of Pts |
Baseline Mean |
End of Study Mean |
Absolute Benefit |
Relative Difference |
Bayramoglu 2003 |
End of treatment |
E: Orthovisc + PT |
Lequesene Index (0‐24) |
16 |
12.4 |
9.1 |
‐1.00 (I) |
‐8.6% (I) |
|
|
C: PT |
|
15 |
11.6 |
9.3 |
|
|
Bayramoglu 2003 |
End of treatment |
E: Orthovisc + PT |
Lequesne Index (0‐24) |
16 |
12.4 |
9.1 |
0.9 (W) |
7.0% (W) |
|
|
C: Hylan G‐F 20 + PT |
|
15 |
12.8 |
8.6 |
|
|
Bayramoglu 2003 |
5‐13 wk |
E: Orthovisc + PT |
Lequesene Index (0‐24) |
16 |
12.4 |
7.6 |
‐2.6 (I) |
‐22.4% (I) |
|
|
C: PT |
|
15 |
11.6 |
9.4 |
|
|
Bayramoglu 2003 |
5‐13 wk |
E: Orthovisc + PT |
Lequesne Index (0‐24) |
16 |
12.4 |
7.6 |
‐0.6 (I) |
‐4.7% (I) |
|
|
C: Hylan G‐F 20 + PT |
|
15 |
12.8 |
8.6 |
|
|
Tascioglu 2003 |
1‐4 wk |
E: Orthovisc |
Pain on weight bearing (0‐100 mm VAS) |
28 |
54.26 |
31.83 |
3.87 (W) |
7.3% (W) |
|
|
C: 6‐MPA |
|
27 |
53.10 |
26.80 |
|
|
Tascioglu 2003 |
1‐4 wk |
E: Orthovisc |
Pain at rest (0‐100 mm VAS) |
28 |
30.43 |
11.83 |
3.00 (W) |
10.0% (W) |
|
|
C: 6‐MPA |
|
27 |
29.90 |
8.30 |
|
|
Tascioglu 2003 |
1‐4 wk |
E: Orthovisc |
Pain on walking (0‐100 mm VAS) |
28 |
67.60 |
37.60 |
1.00 (W) |
1.5% (W) |
|
|
C: 6‐MPA |
|
27 |
69.00 |
38.00 |
|
|
Tascioglu 2003 |
1‐4 wk |
E: Orthovisc |
Lequesne Index (0‐24) |
28 |
10.23 |
7.86 |
‐0.47 (I) |
‐4.8% (I) |
|
|
C: 6‐MPA |
|
27 |
9.86 |
7.96 |
|
|
Tascioglu 2003 |
1‐4 wk |
E: Orthovisc |
Flexion (degrees) |
28 |
108.70 |
116.36 |
1.52 (I) |
1.4% (I) |
|
|
C: 6‐MPA |
|
27 |
108.06 |
114.20 |
|
|
Tascioglu 2003 |
5‐13 wk |
E: Orthovisc |
Pain on weight bearing (0‐100 mm VAS) |
28 |
54.26 |
22.86 |
‐16.80 (I) |
‐31.6% (I) |
|
|
C: 6‐MPA |
|
27 |
53.10 |
38.50 |
|
|
Tascioglu 2003 |
5‐13 wk |
E: Orthovisc |
Pain at rest (0‐100 mm VAS) |
28 |
30.43 |
12.00 |
‐8.23 (I) |
‐27.5% (I) |
|
|
C: 6‐MPA |
|
27 |
29.90 |
19.70 |
|
|
Tascioglu 2003 |
5‐13 wk |
E: Orthovisc |
Pain on walking (0‐100 mm VAS) |
28 |
67.60 |
32.03 |
‐17.03 (I) |
‐24.7% (I) |
|
|
C: 6‐MPA |
|
27 |
69.00 |
50.46 |
|
|
Tascioglu 2003 |
5‐13 wk |
E: Orthovisc |
Lequesne Index (0‐24) |
28 |
10.23 |
7.66 |
‐1.77 (I) |
‐17.9% (I) |
|
|
C: 6‐MPA |
|
27 |
9.86 |
9.06 |
|
|
Tascioglu 2003 |
5‐13 wk |
E: Orthovisc |
Flexion (degrees) |
28 |
108.70 |
115.76 |
1.72 (I) |
1.6% (I) |
|
|
C: 6‐MPA |
|
27 |
108.06 |
113.40 |
|
|
Tascioglu 2003 |
14‐26 wk |
E: Orthovisc |
Pain on weight bearing (0‐100 mm VAS) |
28 |
54.26 |
40.96 |
‐16.56 (I) |
‐31.2% (I) |
|
|
C: 6‐MPA |
|
27 |
53.10 |
56.36 |
|
|
Tascioglu 2003 |
14‐26 wk |
E: Orthovisc |
Pain at rest (0‐100 mm VAS) |
28 |
30.43 |
23.56 |
‐3.43 (I) |
‐11.5% (I) |
|
|
C: 6‐MPA |
|
27 |
29.90 |
26.46 |
|
|
Tascioglu 2003 |
14‐26 wk |
E: Orthovisc |
Pain on walking (0‐100 mm VAS) |
28 |
67.60 |
51.16 |
‐13.50 (I) |
‐19.6% (I) |
|
|
C: 6‐MPA |
|
27 |
69.00 |
66.06 |
|
|
Tascioglu 2003 |
14‐26 wk |
E: Orthovisc |
Lequesne Index (0‐24) |
28 |
10.23 |
8.46 |
‐1.51 (I) |
‐15.3% (I) |
|
|
C: 6‐MPA |
|
27 |
9.86 |
9.60 |
|
|
Tascioglu 2003 |
14‐26 wk |
E: Orthovisc |
Flexion (degrees) |
28 |
108.70 |
114.60 |
4.36 (I) |
4.0% (I) |
|
|
C: 6‐MPA |
|
27 |
108.06 |
109.60 |
|
|
Hizmetli 1999 |
1‐4 wk |
E: Orthovisc |
WOMAC pain (5‐25 Likert) |
20 |
17.75 |
10.20 |
‐7.80 (I) |
‐44.6% (I) |
|
|
C: Saline |
|
20 |
17.45 |
17.70 |
|
|
Hizmetli 1999 |
5‐13 wk |
E: Orthovisc |
WOMAC pain (5‐25 Likert) |
20 |
17.75 |
11.75 |
‐6.25 (I) |
‐35.4% (I) |
|
|
C: Saline |
|
20 |
17.45 |
17.70 |
|
|
Hizmetli 1999 |
14‐26 wk |
E: Orthovisc |
WOMAC pain (5‐25 Likert) |
20 |
17.75 |
12.80 |
‐5.90 (I) |
‐33.7% (I) |
|
|
C: Saline |
|
20 |
17.45 |
18.40 |
|
|
Hizmetli 1999 |
45‐52 wk |
E: Orthovisc |
WOMAC pain (5‐25 Likert) |
20 |
17.75 |
13.80 |
‐5.60 (I) |
‐32% (I) |
|
|
C: Saline |
|
20 |
17.45 |
19.10 |
|
|
Hizmetli 1999 |
1‐4 wk |
E: Orthovisc |
WOMAC function (17‐85 Likert) |
20 |
53.15 |
39.85 |
‐13.40 (I) |
‐25.8% (I) |
|
|
C: Saline |
|
20 |
52.00 |
52.10 |
|
|
Hizmetli 1999 |
5‐13 wk |
E: Orthovisc |
WOMAC function (17‐85 Likert) |
20 |
53.15 |
41.35 |
‐11.30 (I) |
‐21.7 (I) |
|
|
C: Saline |
|
20 |
52.00 |
51.50 |
|
|
Hizmetli 1999 |
14‐26 wk |
E: Orthovisc |
WOMAC function (17‐85 Likert) |
20 |
53.15 |
43.20 |
‐10.45 (I) |
‐20.2 (I) |
|
|
C: Saline |
|
20 |
52.00 |
52.50 |
|
|
Hizmetli 1999 |
46‐52 wk |
E: Orthovisc |
WOMAC function (17‐85 Likert) |
20 |
53.15 |
45.80 |
‐8.25 (I) |
‐16.0 (I) |
|
|
C: Saline |
|
20 |
52.00 |
52.90 |
|
|
Tekeoglu 1998 |
1‐4 wk |
E: Orthovisc |
WOMAC function (17‐85 Likert) |
20 |
45.50 |
34.30 |
3.10 (W) |
6.8% (W) |
|
|
C: Betamethasone |
|
20 |
45.60 |
31.30 |
|
|
Tekeoglu 1998 |
5‐13 wk |
E: Orthovisc |
WOMAC function (17‐85 Likert) |
20 |
45.50 |
30.90 |
‐8.90 (I) |
‐19.5% (I) |
|
|
C: Betamethasone |
|
20 |
45.60 |
39.90 |
|
|
Tekeoglu 1998 |
1‐4 wk |
E: Orthovisc |
Maximum flexion (degrees) |
20 |
110.50 |
117.30 |
0.60 (I) |
0.5% (I) |
|
|
C: Betamethsone |
|
20 |
116.00 |
122.20 |
|
|
Tekeoglu 1998 |
5‐13 wk |
E: Orthovisc |
Maximum flexion (degrees) |
20 |
110.50 |
121.20 |
‐1.55 (W) |
‐1.3% (W) |
|
|
C: Betamethasone |
|
20 |
116.00 |
128.25 |
|
|
Kalay 1997 |
1‐4 wk |
E: Orthovisc + PT |
Activity pain (0‐100 mm VAS) |
20 |
46.8 |
12.50 |
‐11.4 (I) |
‐30.7% (I) |
|
|
C: PT |
|
20 |
37.1 |
14.20 |
|
|
Kalay 1997 |
1‐4 wk |
E: Orthovisc + PT |
Spontaneous pain (0‐100 mm VAS) |
20 |
26.1 |
5.80 |
‐3.6 (W) |
‐16.3% (W) |
|
|
C: PT |
|
20 |
22.1 |
5.40 |
|
|
Kalay 1997 |
1‐4 wk |
E: Orthovisc + PT |
Night pain (0‐100 mm VAS) |
20 |
24.3 |
5.40 |
‐2.8 (I) |
‐12.9% (I) |
|
|
C: PT |
|
20 |
21.7 |
5.60 |
|
|
Kalay 1997 |
1‐4 wk |
E: Orthovisc + PT |
25 m walk time (sec) |
20 |
22.4 |
15.30 |
‐3.10 (I) |
‐16.7% (I) |
|
|
C: PT |
|
20 |
18.6 |
14.60 |
|
|
Kalay 1997 |
1‐4 wk |
E: Orthovisc + PT |
Flexion (degrees) |
20 |
126.00 |
130.00 |
2.70 (I) |
2.1% (I) |
|
|
C: PT |
|
20 |
128.50 |
129.80 |
|
|
Kalay 1997 |
5‐13 wk |
E: Orthovisc + PT |
Activity pain (0‐100 mm VAS) |
20 |
46.8 |
6.10 |
‐16.2 (I) |
‐43.7% (I) |
|
|
C: PT |
|
20 |
37.1 |
12.60 |
|
|
Kalay 1997 |
5‐13 wk |
E: Orthovisc + PT |
Spontaneous pain (0‐100 mm VAS) |
20 |
26.1 |
1.70 |
‐8.1 (I) |
‐16.3% (I) |
|
|
C: PT |
|
20 |
22.1 |
5.80 |
|
|
Kalay 1997 |
5‐13 wk |
E: Orthovisc + PT |
Night pain (0‐100 mm VAS) |
20 |
24.3 |
1.60 |
‐5.9 (I) |
‐27.2% (I) |
|
|
C: PT |
|
20 |
21.7 |
4.90 |
|
|
Kalay 1997 |
5‐13 wk |
E: Orthovisc + PT |
25 m walk time (sec) |
20 |
22.4 |
13.30 |
‐4.90 (I) |
‐26.3% (I) |
|
|
C: PT |
|
20 |
18.6 |
14.40 |
|
|
Kalay 1997 |
5‐13 wk |
E: Orthovisc + PT |
Flexion (degrees) |
20 |
126.00 |
130.00 |
2.70 (I) |
2.1% (I) |
|
|
C: PT |
|
20 |
128.50 |
129.80 |
|
|
Karatay 2004 |
1‐4 wk |
E: Orthovisc |
WOMAC pain (0‐20 Likert) |
20 |
11.2 |
6.4 |
‐0.8 (I) |
‐7.4% (I) |
|
|
C: Hylan G‐F 20 |
|
20 |
10.8 |
6.2 |
|
|
Karatay 2004 |
1‐4 wk |
E: Orthovisc |
WOMAC function (0‐68 Likert) |
20 |
35.0 |
7.4 |
‐3.2 (I) |
‐10.0% (I) |
|
|
C: Hylan G‐F 20 |
|
20 |
31.9 |
7.5 |
|
|
Karatay 2004 |
1‐4 wk |
E: Orthovisc |
WOMAC stiffness (0‐8 Likert) |
20 |
3.8 |
1.8 |
‐0.2 (I) |
‐5.6% (I) |
|
|
C: Hylan G‐F 20 |
|
20 |
3.6 |
1.8 |
|
|
Karatay 2004 |
1‐4 wk |
E: Orthovisc |
SF intercellular adhesion molecule‐1 (ICAM‐1) |
20 |
19.2 |
11.1 |
‐0.3 (I) |
‐1.7% (I) |
|
|
C: Hylan G‐F 20 |
|
20 |
17.8 |
10.0 |
|
|
Karatay 2004 |
1‐4 wk |
E: Orthovisc |
SF vascular cell adhesion molecule‐1 (VCAM) |
20 |
40.5 |
14.2 |
1.3 (W) |
3.4% (W) |
|
|
C: Hylan G‐F 20 |
|
20 |
37.8 |
10.2 |
|
|